ストックスクリーナーアプリを入手
1.24
2.48%
0.03
アフターアワーズ：
1.21
-0.03
-2.42%
前日終値:
$1.21
開ける：
$1.2
24時間の取引高:
249.65K
Relative Volume:
0.60
時価総額：
$59.68M
収益：
$19.94M
当期純損益:
$-37.37M
株価収益率:
-1.1923
EPS:
-1.04
ネットキャッシュフロー:
$-33.38M
1週間 パフォーマンス:
+0.81%
1か月 パフォーマンス:
+11.71%
6か月 パフォーマンス:
-16.22%
1年 パフォーマンス:
-57.09%
1日の値動き範囲:
$1.19
$1.27
1週間の範囲:
$1.19
$1.345
52週間の値動き範囲:
$0.595
$4.18
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
名前
Werewolf Therapeutics Inc
セクター
電話
617-952-0555
住所
200 TALCOTT AVENUE, WATERTOWN
HOWL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.24 | 59.68M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-03 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-24 | 開始されました | Wedbush | Outperform |
| 2023-06-06 | 再開されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-25 | 開始されました | Evercore ISI | Outperform |
| 2021-05-25 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-25 | 開始されました | Jefferies | Buy |
| 2021-05-25 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Werewolf Therapeutics Inc (HOWL) 最新ニュース
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know - MSN
Werewolf Therapeutics Adopts New Bylaws and Elects Directors - TipRanks
Two Sigma Investments LP Sells 87,168 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics to Participate in the BIO International Convention - GlobeNewswire
Jane Street Group LLC Acquires 39,564 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Two Sigma Advisers LP Sells 117,200 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Sold by Millennium Management LLC - Defense World
Deutsche Bank AG Buys 83,172 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Northern Trust Corp Acquires 16,640 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Bank of America Corp DE Lowers Stock Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics Announces Q1 2025 Financial Results - MSN
Werewolf Therapeutics Leaders to Reveal Latest Cancer Treatment Progress at Major Healthcare Conference - Stock Titan
Werewolf Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference - GlobeNewswire
D. E. Shaw & Co. Inc. Makes New Investment in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy Rating Maintained | HOWL Stock News - GuruFocus
Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy R - GuruFocus
Werewolf Therapeutics (HOWL) Stock Price, News & Analysis - MarketBeat
Werewolf Therapeutics’ SWOT analysis: innovative platform drives stock potential By Investing.com - Investing.com Nigeria
Werewolf Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com Australia
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 - GlobeNewswire
Breakthrough Skin Cancer Treatment: Patient Cancer-Free After 1 Year in Revolutionary IL-2 Drug Trial - Stock Titan
Dimensional Fund Advisors LP Cuts Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics Receives Nasdaq Deficiency Notice - TipRanks
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit - GlobeNewswire
Wedbush Cuts Werewolf Therapeutics (NASDAQ:HOWL) Price Target to $6.00 - Defense World
Werewolf Therapeutics First Quarter 2025 Earnings: US$0.40 loss per share (vs US$0.39 loss in 1Q 2024) - Yahoo Finance
Wedbush Adjusts Price Target on WEREWOLF THERAPEUTICS (HOWL) to USD 6.00 | HOWL Stock News - GuruFocus
H.C. Wainwright cuts Werewolf Therapeutics target to $10 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts Werewolf Therapeutics target to $10 - Investing.com Australia
Wedbush Adjusts Price Target on Werewolf Therapeutics to $6 From $8, Maintains Outperform Rating - marketscreener.com
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Reports Q1 2025 Financial Results - TipRanks
Werewolf Therapeutics (HOWL) Advances Clinical Trials and Expands Educational Initiatives | HOWL Stock News - GuruFocus
Werewolf Therapeutics Announces Progress in Clinical Trials and Financial Updates for Q1 2025 - Nasdaq
Renaissance Technologies LLC Decreases Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
JPMorgan Chase & Co. Raises Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
HOWLWerewolf Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Werewolf Therapeutics (HOWL) Showcases Innovative IBD Treatment Developments | HOWL Stock News - GuruFocus
Werewolf Therapeutics reports progress on IBD treatment - Investing.com Australia
Werewolf Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Werewolf Therapeutics Inc (HOWL) 財務データ
収益
当期純利益
現金流量
EPS
Werewolf Therapeutics Inc (HOWL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 14 '25 |
Buy |
0.98 |
162,539 |
159,288 |
6,237,482 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 13 '25 |
Buy |
0.98 |
52,974 |
51,915 |
6,074,943 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Mar 27 '25 |
Sale |
1.05 |
1,963 |
2,061 |
3,208,793 |
| EVNIN LUKE | Director |
Mar 27 '25 |
Sale |
1.05 |
2,425 |
2,546 |
4,309,860 |
| GADICKE ANSBERT | 10% Owner |
Mar 27 '25 |
Sale |
1.05 |
4,386 |
4,605 |
6,718,670 |
2.13%
1.01%
大文字化:
|
ボリューム (24 時間):